Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

ns and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen
Ashleigh Koss: 805-313-6151 (media)
Arvind Sood: 805-447-1060 (investors)

'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to ... County (New Jersey) Chamber of Commerce as a ... organization in the North Jersey area, offers Whitehouse ... key clients in the pharmaceutical and biotechnology areas ... Membership enables Whitehouse Laboratories a higher level of ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... a subsidiary of MGT Capital Investments, Inc. (NYSE Alternext ... of Computer-Aided Detection (CAD) and image analysis software which ... is pleased to announce it has launched ColonCAD API ... today at the European Congress of Radiology (ECR 2009) ...
... All amounts are in US dollarsQUEBEC CITY, March ... AEZS ; TSX: AEZ), a global biopharmaceutical ... announced the signing of a development, commercialization and ... SNY ) for the development, registration and ...
... in the two years since its discovery, has spread to ... half a million bats. Now researchers have suggested the first ... bats: providing localized heat sources to the hibernating animals. ... says Justin Boyles, a graduate student in biology at Indiana ...
Cached Biology Technology:Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009 2Medicsight Unveils New Version of ColonCAD(TM) at ECR 2009 3AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia 5Ecologists propose first prevention for white-nose syndrome death in bats 2Ecologists propose first prevention for white-nose syndrome death in bats 3
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... Research and Markets has announced the addition of ... Companies" to their offering. This report ... already started to play an important role in the practice ... fashioned bone marrow transplants. Role of cells in drug discovery ... part of medical practice. Stem cells are discussed ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... February 23, 2009 - A new study by ... Panel on Climate Change (IPCC) 2001 Third Assessment Report ... average global temperatures due to greenhouse gas emissions could ... concern. The study, published in the Proceedings of ...
... California Institute of Technology (Caltech) and the University of ... theoretical modeling and Caltech experimental data to show just ... functional proteins. Their insights were recently published in ... the National Academy of Sciences (PNAS). The ...
... Maybe. A team of European scientists have finally solved a ... gray. Despite the notion that gray hair is a sign of ... The FASEB Journal ( http://www.fasebj.org ) that wisdom has ... massive build up of hydrogen peroxide due to wear and tear ...
Cached Biology News:Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3Caltech and UCSD researchers shed light on how proteins find their shapes 2No longer a gray area: Our hair bleaches itself as we grow older 2
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Rad1 MAb (Clone 33)...
Biology Products: